EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Blood

Volumn 118, Issue 15, 2011, Pages 4024-4035

  Kempf, Werner ^a,b   Pfaltz, Katrin ^b   Vermeer, Maarten H ^c   Cozzio, Antonio ^a   Ortiz Romero, Pablo L ^d   Bagot, Martine ^e   Olsen, Elise ^f   Kim, Youn H ^g   Dummer, Reinhard ^a   Pimpinelli, Nicola ^h   Whittaker, Sean ⁱ   Hodak, Emmilia ^j   Cerroni, Lorenzo ^k   Berti, Emilio ^l   Horwitz, Steve ^m   Prince, H Miles ⁿ   Guitart, Joan ^o   Estrach, Teresa ^p   Sanches, José A ^q   Duvic, Madeleine ^r   Ranki, Annamari ^s   Dreno, Brigitte ^t   Ostheeren Michaelis, Sonja ^b   Knobler, Robert ^u   Wood, Gary ^v   Willemze, Rein ^c   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Histologic Diagnostics   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e SAINT LOUIS HOSPITAL   (France)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ ST THOMAS HOSPITAL   (United Kingdom)

^j TEL AVIV UNIVERSITY   (Israel)

^k Universitatsklinik fur Dermatologie und Venerologie   (Austria)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o NORTHWESTERN UNIVERSITY   (United States)

^p UNIVERSITY OF BARCELONA   (Spain)

^q UNIVERSITY OF SÃO PAULO   (Brazil)

^r University of Texas Health Science Center at Houston   (United States)

^s HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^t NANTES UNIVERSITY HOSPITAL   (France)

^u Universitatsklinik fur Dermatologie   (Austria)

^v UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BEXAROTENE; BRENTUXIMAB VEDOTIN; CARMUSTINE; CD30 LIGAND; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; GAMMA INTERFERON; GEMCITABINE; IMIQUIMOD; ISOTRETINOIN; METHOTREXATE; MILTEFOSINE; PENICILLIN DERIVATIVE; PREDNISONE; PSORALEN; SGN 30; STEROID; SULFONE DERIVATIVE; TACROLIMUS; TETRACYCLINE DERIVATIVE; THALIDOMIDE; VINCRISTINE;

ABDOMINAL RADIOGRAPHY; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER; EXCIMER LASER; EXCISION; FOLLOW UP; HISTOLOGY; HUMAN; INFORMATION RETRIEVAL; INTERNATIONAL SOCIETY FOR CUTANEOUS LYMPHOMA; LABORATORY TEST; LARGE CELL LYMPHOMA; LASER THERMOTHERAPY; LOW DRUG DOSE; LYMPHOMATOID PAPULOSIS; MEDICAL SOCIETY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PUVA; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR CELL; UNITED STATES CUTANEOUS LYMPHOMA CONSORTIUM; VISCUM ALBUM;

EID: 80054119243     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-351346     Document Type: Conference Paper

References (116)

1. Willemze R, Jaffe ES, Burg G, et al. WHOEORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
2. Kempf W, Willemze R, Jaffe ES, Burg G, Kadin ME. CD30+ T-cell lymphoproliferative disorders. In: LeBoit P, Burg G, Weedon D, Sarasin A, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006;179-181.
3. Ralfkiaer E, Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed). Lyon, France: IARC Press; 2008;300-301.
4. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the longterm follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95(12):3653-3661. (Pubitemid 30412833)
5. Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park). 2009;23(13): 1158-1164.
6. Vergier B, Beylot-Barry M, Pulford K, et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol. 1998;22(10):1192-1202. (Pubitemid 28462767)
7. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009; 145(12):1399-1404.
8. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003; 49(6):1049-1058. (Pubitemid 37475476)
9. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973-980. (Pubitemid 23160651)
10. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med. 1995;122(3):210-217.
11. Laube S, Shah F, Marsden J. Consequences of misdiagnosis of lymphomatoid papulosis. Eur J Cancer Care (Engl). 2006;15(2):194-198. (Pubitemid 43542761)
12. Kaufmann T, Nisce LZ, Silver RT. Lymphomatoid papulosis: case report of a patient managed with radiation therapy and review of the literature. Am J Clin Oncol. 1992;15(5):412-416.
13. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine therapy for lymphomatoid papulosis. Arch Dermatol. 1985;121(11):1410-1414. (Pubitemid 16216782)
14. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 2010;24(7):574-587.
15. Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982; 107(2):131-144. (Pubitemid 12041532)
16. Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: description of 9 cases. Am J Surg Pathol. 2010;34(8):1168-1175.
17. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. 2006; 33(suppl):158-170.
18. Guitart J, Querfeld C. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue. Semin Diagn Pathol. 2009;26(3):131- 140.
19. Benner MF, Willemze R. Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin: retrospective analysis of 107 patients. Br J Dermatol. 2008;159(5):1148-1151.
20. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484. (Pubitemid 47105384)
21. Kaudewitz P, Stein H, Dallenbach F, et al. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas: morphologic, immunohistologic, and clinical characteristics. Am J Pathol. 1989;135(2):359-367. (Pubitemid 19240220)
22. Banerjee SS, Heald J, Harris M. Twelve cases of Ki-1 positive anaplastic large cell lymphoma of skin. J Clin Pathol. 1991;44(2):119-125.
23. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer. 1993;71(6): 2097-2104. (Pubitemid 23068561)
24. Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30-positive anaplastic large cell lymphoma: report of 27 cases. J Cutan Pathol. 1993;20(3):193-202. (Pubitemid 23210536)
25. de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23(2): 127-135. (Pubitemid 23255259)
26. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases. A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13(6):1343-1354.
27. Trautmann C, Hahnemann HG, Hilbert ET, Detmar M, Gollnick H, Orfanos CE. [Large cell anaplastic Ki-1 positive lymphoma of the skin: 5 personal cases and review of the literature]. Hautarzt. 1995;46(1):28-34.
28. Shah SA, Ormerod AD, Husain A, Kohle P, Culligan D. Primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma associated with renal cell carcinoma. Br J Dermatol. 1999; 140(5):971-972. (Pubitemid 29238483)
29. Berti E, Gianotti R, Alessi E. Primary anaplastic large cell lymphoma of the skin. Dermatologica. 1989;178(4):225-227. (Pubitemid 19173987)
30. Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1542-1545. (Pubitemid 351417771)
31. Chou WC, Su IJ, Tien HF, et al. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: special emphasis on the tumor response to 13-cis retinoic acid. Cancer. 1996;78(8):1805-1812.
32. Kaufmann TP, Coleman M, Nisce LZ. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Cancer Invest. 1997;15(2):91- 97.
33. Chung HG, Chung YL, Kang JM, et al. CD30 (Ki- 1)-positive large-cell cutaneous T-cell lymphoma with secondary xanthomatous changes after radiation therapy. J Am Acad Dermatol. 2003;48(2 suppl):S28-S30. (Pubitemid 36231883)
34. Koreen IV, Cho RI, Frueh BR, Elner VM. Primary cutaneous anaplastic large cell lymphoma of the medial canthus and orbit. Ophthal Plast Reconstr Surg. 2009;25(1):63-65.
35. Shimizu Y, Tanae K, Takahashi N, et al. Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res. 2010;34(2):263-266.
36. Stenier C, Bourlond A, Humblet Y. Ki-1 anaplastic primary cutaneous large-cell lymphoma. Dermatology. 1995;190(4):332-334.
37. Asha LK, Thomas D, Binitha MP, Nandakumar G. Primary cutaneous multifocal CD30+ anaplastic large cell lymphoma. Indian J Dermatol Venereol Leprol. 2006;72(5):376-378. (Pubitemid 44579171)
38. Fujita H, Nagatani T, Miyazawa M, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. Eur J Dermatol. 2008;18(3):360-361. (Pubitemid 351821261)
39. Sheehy O, Catherwood M, Pettengell R, Morris TC. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. Leuk Lymphoma. 2009;50(8):1389-1391.
40. Shehan JM, Kalaaji AN, Markovic SN, Ahmed I. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol. 2004;51(1):103-110. (Pubitemid 38898663)
41. Boudova L, Kazakov DV, Jindra P, et al. Primary cutaneous histiocyte and neutrophil-rich CD30+and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol. 2006;33(8):584-589. (Pubitemid 44213862)
42. Isogai R, Fukao M, Kawada A. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in an elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP- B) therapy. J Dermatol. 2007;34(8):556- 560.
43. Diamantidis MD, Papadopoulos A, Kaiafa G, et al. Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task. Int J Hematol. 2009;90(2): 226-229.
44. Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R. Oral etoposide in the treatment of cutaneous large-cell lymphomas: a preliminary report of four cases. Br J Dermatol. 1992; 127(5):524-528.
45. Brice P, Cazals D, Mounier N, et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia. 1998;12(2):213-219. (Pubitemid 28108074)
46. Yamane N, Kato N, Nishimura M, Ito M, Yanagi T, Osawa R. Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide. Clin Exp Dermatol. 2009;34(5): e56-e59.
47. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008; 111(4):1848-1854. (Pubitemid 351451492)
48. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19): 6217-6224.
49. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): 1812-1821.
50. French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol. 2001;45(6):914- 918.
51. Hazneci E, Aydin NE, Dogan G, Turhan IO. Primary cutaneous anaplastic large cell lymphoma in a young girl. J Eur Acad Dermatol Venereol. 2001;15(4):366-367. (Pubitemid 33014860)
52. Keun YK, Woodruff R, Sangueza O. Response of CD30+ large cell lymphoma of skin to bexarotene. Leuk Lymphoma. 2002;43(5):1153-1154. (Pubitemid 34460903)
53. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol. 2004;150(6): 1198-1201. (Pubitemid 38932294)
54. Ehst BD, Dreno B, Vonderheid EC. Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. Eur J Dermatol. 2008;18(4):467-468. (Pubitemid 352031866)
55. Lee JH, Cheng AL, Lin CW, Kuo SH. Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application. Br J Dermatol. 2009;160(4):887-889.
56. Bernier M, Bagot M, Broyer M, Farcet JP, Gaulard P, Wechsler J. Distinctive clinicopathologic features associated with regressive primary CD30 positive cutaneous lymphomas: analysis of 6 cases. J Cutan Pathol. 1997;24(3):157-163. (Pubitemid 27117371)
57. Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES. Primary cutaneous CD30- positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol. 2005;8(1):52-60. (Pubitemid 40568920)
58. .Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667-674.
59. .Wantzin GL, Thomsen K. PUVA-treatment in lymphomatoid papulosis. Br J Dermatol. 1982; 107(6):687-690. (Pubitemid 13238868)
60. Lange-Wantzin G, Thomsen K, Hou-Jensen K. Lymphomatoid papulosis: a follow-up study. Acta Derm Venereol. 1984;64(1):46-51. (Pubitemid 14179567)
61. Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. Br J Dermatol. 1984; 111(1):93-95. (Pubitemid 14086232)
62. Barnadas MA, Lopez D, Pujol RM, Garcia-Patos V, Curell R, de Moragas JM. Pustular lymphomatoid papulosis in childhood. J Am Acad Dermatol. 1992;27(4):627-628.
63. .Wolf P, Cohen PR, Duvic M. Ambivalent response of lymphomatoid papulosis treated with 8-methoxypsoralen and UVA. J Am Acad Dermatol. 1994;30(6):1018-1020. (Pubitemid 24166576)
64. Volkenandt M, Kerscher M, Sander C, Meurer M, Rocken M. PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol. 1995;131(9):1094.
65. Gambichler T, Maushagen E, Menzel S. Foil bath PUVA in lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 1999;13(1):63-65. (Pubitemid 29475061)
66. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic largecell lymphoma of the small bowel. Clin Lymphoma. 2004;5(3):190-193. (Pubitemid 40227711)
67. Korpusik D, Ruzicka T. [Clinical course and therapy of lymphomatoid papulosis: experience with 17 cases and literature review]. Hautarzt. 2007;58(10):870-881.
68. Hoetzenecker W, Guenova E, Hoetzenecker K, Yazdi A, Rocken M, Berneburg M. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol. 2009;19(6):646-647.
69. de Souza A, Camilleri MJ, Wada DA, Appert DL, Gibson LE, el-Azhary RA. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009; 61(6):993-1000.
70. Calzavara-Pinton P, Venturini M, Sala R. Medium- dose UVA1 therapy of lymphomatoid papulosis. J Am Acad Dermatol. 2005;52(3):530-532.
71. Van Neer FJ, Toonstra J, Van Voorst Vader PC, Willemze R, Van Vloten WA. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br J Dermatol. 2001;144(2):351-354. (Pubitemid 32178818)
72. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140(3):306-312. (Pubitemid 38332482)
73. Lynch PJ, Saied NK. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis. 1979;23(5):634-636. (Pubitemid 9167853)
74. Everett MA. Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol. 1984; 111(5):631. (Pubitemid 15200170)
75. .Wantzin GL, Thomsen K, Brandrup F, Larsen JK. Lymphomatoid papulosis: development into cutaneous T-cell lymphoma. Arch Dermatol. 1985; 121(6):792-794. (Pubitemid 15051673)
76. Thomsen K, Wantzin GL. Lymphomatoid papulosis: a follow-up study of 30 patients. J Am Acad Dermatol. 1987;17(4):632-636. (Pubitemid 17147807)
77. Christensen HK, Thomsen K, Vejlsgaard GL. Lymphomatoid papulosis: a follow-up study of 41 patients. Semin Dermatol. 1994;13(3):197-201. (Pubitemid 24276937)
78. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30- positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34(3):470-481. (Pubitemid 26083827)
79. Bergstrom JS, Jaworsky C. Topical methotrexate for lymphomatoid papulosis. J Am Acad Dermatol. 2003;49(5):937-939. (Pubitemid 37314896)
80. Hughes PS. Treatment of lymphomatoid papulosis with imiquimod 5% cream. J Am Acad Dermatol. 2006;54(3):546-547. (Pubitemid 43243469)
81. Romero-Mate A, Martin-Fragueiro L, Minano-Medrano R, Martinez-Moran C, Arias- Palomo D, Borbujo J. Persistent agmination of lymphomatoid papulosis evolving to classical lesions of lymphomatoid papulosis. J Am Acad Dermatol. 2009;61(6):1087-1088.
82. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3): 416-428. (Pubitemid 19086776)
83. Scheen SR 3rd, Doyle JA, Winkelmann RK. Lymphoma- associated papulosis: lymphomatoid papulosis associated with lymphoma. J Am Acad Dermatol. 1981;4(4):451-457.
84. Sanchez NP, Pittelkow MR, Muller SA, Banks PM, Winkelmann RK. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. J Am Acad Dermatol. 1983;8(1):81- 94.
85. Sina B, Burnett JW. Lymphomatoid papulosis: case reports and literature review. Arch Dermatol. 1983;119(3):189-197. (Pubitemid 13151958)
86. Zirbel GM, Gellis SE, Kadin ME, Esterly NB. Lymphomatoid papulosis in children. J Am Acad Dermatol. 1995;33(5):741-748.
87. Paul MA, Krowchuk DP, Hitchcock MG, Jorizzo JL. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol. 1996;13(6):501-506. (Pubitemid 27009821)
88. Kagaya M, Kondo S, Kamada A, Yamada Y, Matsusaka H, Jimbow K. Localized lymphomatoid papulosis. Dermatology. 2002;204(1):72-74. (Pubitemid 34136819)
89. Dalle S, Balme B, Thomas L. Lymphomatoid papulosis localized to the face. Dermatol Online J. 2006;12(3):9.
90. Bories N, Thomas L, Phan A, et al. [Lymphomatoid papulosis in childhood: six case reports and a literature review]. Ann Dermatol Venereol. 2008; 135(10):657-662.
91. Proctor SJ, Jackson GH, Lennard AL, Marks J. Lymphomatoid papulosis: response to treatment with recombinant interferon alfa-2b. J Clin Oncol. 1992;10(1):170.
92. .Wyss M, Dummer R, Dommann SN, et al. Lymphomatoid papulosis: treatment with recombinant interferon alfa-2a and etretinate. Dermatology. 1995;190(4):288-291.
93. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferongamma. J Invest Dermatol. 1996;107(6):827-832. (Pubitemid 26408199)
94. Schmuth M, Topar G, Illersperger B, Kowald E, Fritsch PO, Sepp NT. Therapeutic use of interferon- alpha for lymphomatoid papulosis. Cancer. 2000;89(7):1603-1610.
95. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206(2):142-147. (Pubitemid 36205282)
96. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147(4):443-449.
97. Knol AC, Ehst BD, Dompmartin A, et al. Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. Br J Dermatol. 2009;161(6):1414-1416.
98. Thomsen K, Hjort G, Svendsen D. Lymphomatoid papulosis. Dermatologica. 1972;144(2):65-74.
99. Scarisbrick JJ, Evans AV, Woolford AJ, Black MM, Russell-Jones R. Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol. 1999; 141(6):1125-1128. (Pubitemid 30046209)
100. Deroo-Berger MC, Skowron F, Ronger S, et al. Lymphomatoid papulosis: a localized form with acral pustular involvement. Dermatology. 2002; 205(1):60-62. (Pubitemid 36152964)
101. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011;29(18): 2598-2607.
102. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999;86(7):1368- 1376. (Pubitemid 29447025)
103. Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol. 1999;40(5):857-861. (Pubitemid 29230344)
104. Blume JE, Stoll HL, Cheney RT. Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate. J Am Acad Dermatol. 2006;54(5 suppl):S229-S230.
105. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51- 58.
106. Meisenheimer JL. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule. J Drugs Dermatol. 2007; 6(4):440-442.
107. Honma M, Hashimoto M, Iwasaki T, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with local thermotherapy using pocket hand warmers. J Dermatol. 2008;35(11): 748-750.
108. el-Azhary RA, Gibson LE, Kurtin PJ, Pittelkow MR, Muller SA. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol. 1994; 30(2):210-218. (Pubitemid 24051885)
109. Assaf C, Hirsch B, Wagner F, et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol. 2007;127(8):1898-1904. (Pubitemid 47075358)
110. Coelho JD, Afonso A, Feio AB. Regional lymphomatoid papulosis in a child: treatment with a UVB phototherapy handpiece. J Cosmet Laser Ther. 2010;12(3):155-156.
111. Dummer R, Krasovec M, Roger J, Sindermann H, Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Acad Dermatol. 1993;29(6):963-970. (Pubitemid 23360329)
112. Wollina U. Lymphomatoid papulosis treated with extracorporeal photochemotherapy. Oncol Rep. 1998;5(1):57-59. (Pubitemid 28039818)
113. Rodrigues M, McCormack C, Yap LM, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy. Australas J Dermatol. 2009;50(2):129-132.
114. Baumgartner G, Duschet P, Schwarz T, Partsch H, Gschnait F, Stacher A. Lymphomatoid papulosis: remission following intravenously administered acyclovir. Dermatologica. 1986; 172(6):305-309. (Pubitemid 16014780)
115. Burg G, Klepzig K, Kaudewitz P, Wolff H, Braun-Falco O. [Acyclovir in mycosis fungoides and lymphomatoid papulosis]. Hautarzt. 1986; 37(10):533-536.
116. Seifert G, Tautz C, Seeger K, Henze G, Laengler A. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/ lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2007;21(4):558-560. (Pubitemid 46454926)